Latham & Watkins Advises Eleusis in US$446 Million Merger With Silver Spike Acquisition Corp. II

Eleusis, one of the leading companies focusing on the potential of psychedelic science and the delivery of psychedelic medicine for the improvement of depression and other mental health illnesses, and Silver Spike Acquisition Corp. II, a publicly traded special purpose acquisition company sponsored by an affiliate of Silver Spike Capital, have announced that they signed a definitive business combination agreement expected to make Eleusis a public company.

Latham & Watkins LLP represents Eleusis in the transaction with a transactional team led by Bay Area/New York partner Josh Dubofsky, Orange County partner Drew Capurro, New York partner Erika Weinberg, New York associate Kristin Rulison, Bay Area partner Haim Zaltzman, and associates Faisal Amin, Christopher Lloyd, Raul Gonzalez, David Califano, and Francisco Lascurain.  Advice was also provided on UK corporate matters by London partners Robbie McLaren and Douglas Abernethy and associates Alayna Kenney and Hafza Hussein; on tax matters by New York partner Matthew Dewitz, London partner Karl Mah, and London counsel James Leslie; on benefits and compensation matters by London partners Sarah Gadd and Kendall Burnett and New York partner Austin Ozawa, and associates Daniel Gocek and Adam Ray; on intellectual property matters by Bay Area partner Christopher Hazuka; on healthcare regulatory matters by Washington, D.C. partner Elizabeth Richards, Paris/Brussels partner Eveline Van Keymeulen, and Bay Area counsel Betty Pang; on real estate matters by New York counsel Shira Bressler; on antitrust matters by Washington, D.C. counsels Peter Todaro and Joe Simei; on Investment Company Act matters by Chicago partner Laura Ferrell; on CFIUS matters by Washington, D.C. partner Damara Chambers, and on general corporate matters by Boston/New York partner Kristen Grannis and London partner Emily Cridland.